Comparison of [11C]Choline ([11C]CHO) and [18F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model

Molecular Imaging and Biology

Volumn 18, Issue 3, 2016, Pages 393-401

  Schwarzenböck, Sarah Marie ^a,b   Schmeja, Philipp ^b   Kurth, Jens ^b   Souvatzoglou, Michael ^a,f   Nawroth, Roman ^a   Treiber, Uwe ^a   Kundt, Guenther ^b   Berndt, Sandra ^c   Graham, Keith ^c   Senekowitsch Schmidtke, Reingard ^a   Schwaiger, Markus ^a   Ziegler, Sibylle I ^a   Dinkelborg, Ludger ^d   Wester, Hans Jürgen ^e   Krause, Bernd Joachim ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c BAYER PHARMA AG   (Germany)

^d Piramal Enterprises Limited   (India)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF ULM   (Germany)

Author keywords

Bombesin; Choline; Prostate cancer; Small animal PET CT; Xenograft mouse model

Indexed keywords

BOMBESIN F 18; CHOLINE C 11; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BAY 86-4367; BOMBESIN; CARBON; CHOLINE; FLUORINE; MOLECULAR PROBE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; KIDNEY TUBULE ABSORPTION; MALE; MOUSE; NONHUMAN; PET-CT SCANNER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG SCREENING; MOLECULAR PROBE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSTATE TUMOR; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; BOMBESIN; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MICE; MOLECULAR PROBES; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944684934     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0901-1     Document Type: Article

References (32)

1. Price DT, Coleman RE, Liao RP et al (2002) Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168:273–280
2. Zheng QH, Gardner TA, Raikwar S et al (2004) [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 12:2887–2893
3. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC (2002) Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 21:937–946
4. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R et al (2002) Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296:580–583
5. Hara T, Bansal A, DeGrado TR (2006) Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 5:498–509
6. Katz-Brull R, Degani H (1996) Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 16:1375–1380
7. Schwarzenboeck SM, Gertz J, Souvatzoglou M et al (2015) Comparison of [(11)C]choline ([(11)C]CHO) and S(+)-beta-methyl-[(11)C]choline ([(11)C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model. Mol Imaging Biol 17:248–256
8. Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59:1152–1159
9. Honer M, Mu L, Stellfeld T et al (2011) 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med 52:270–278
10. Bergmann R, Ruffani A, Graham B et al (2013) Synthesis and radiopharmacological evaluation of (6)(4)Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator. Eur J Med Chem 70:434–446
11. Mansi R, Wang X, Forrer F et al (2009) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240–5249
12. Nanda PK, Pandey U, Bottenus BN et al (2012) Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol 39:461–471
13. Nock B, Nikolopoulou A, Chiotellis E et al (2003) [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30:247–258
14. Pan D, Xu YP, Yang RH et al (2014) A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Amino Acids 46:1481–1489
15. Pan D, Yan Y, Yang R et al (2014) PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. Contrast Media Mol Imaging 9:342–348
16. Richter S, Wuest M, Krieger SS et al (2013) Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nucl Med Biol 40:1025–1034
17. Varasteh Z, Aberg O, Velikyan I et al (2013) In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. PLoS One 8:e81932
18. Yang M, Gao H, Zhou Y et al (2011) F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics 1:220–229
19. Zhang H, Abiraj K, Thorek DL et al (2012) Evolution of bombesin conjugates for targeted PET imaging of tumors. PLoS One 7:e44046
20. Sah BR, Burger IA, Schibli R et al (2015) Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med 56:372–378
21. Schroeder RP, van Weerden WM, Krenning EP et al (2011) Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 38:1257–1266
22. Cescato R, Maina T, Nock B et al (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49:318–326
23. Abd-Elgaliel WR, Gallazzi F, Garrison JC et al (2008) Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem 19:2040–2048
24. Hara T, Yuasa M (1999) Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging. Appl Radiat Isot 50:531–533
25. Henriksen G, Herz M, Hauser A et al (2004) Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC). Nucl Med Biol 31:851–858
26. Bao Q, Newport D, Chen M et al (2009) Performance evaluation of the Inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 50:401–408
27. Mu L, Honer M, Becaud J et al (2010) In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem 21:1864–1871
28. Zhang X, Cai W, Cao F et al (2006) 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 47:492–501
29. Benesova M, Schafer M, Bauder-Wust U et al (2015) Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56:914–920
30. Lesche R, Kettschau G, Gromov AV et al (2014) Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 41:89–101
31. Weineisen M, Schottelius M, Simecek J et al (2015) 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med 56:1169–1176
32. Weineisen M, Simecek J, Schottelius M et al (2014) Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res 4:63